购物车
- 全部删除
- 您的购物车当前为空
IL-2 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 15.4 kDa and the accession number is P60568.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
20 μg | ¥ 760 | 现货 | |
100 μg | ¥ 1,650 | 5日内发货 | |
1 mg | ¥ 10,800 | 5日内发货 |
生物活性 | 1.Measured in a cell proliferation assay using CTLL‑2 mouse cytotoxic T cells. The ED50 for this effect is 0.5-2.5 ng/mL.
2. Immobilized CD25/IL2RA Protein,Human,Recombinant (ECD,hFc Tag) at 2 μg/ml (100 μl/well) can bind Recombinant Human IL2 Protein,Low Endotoxin, the EC50 is 2-8 ng/mL. |
产品描述 | IL-2 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 15.4 kDa and the accession number is P60568. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | Tag Free |
蛋白编号 | P60568 |
别名 | 白细胞介素,白介素,TCGF,lymphokine,Interleukin-2,interleukin 2,IL-2 |
蛋白构建 | A DNA sequence encoding the human IL2 (NP_000577.2) (Ala21-Thr153) was expressed. Predicted N terminal: Ala 21 |
蛋白纯度 | > 95 % as determined by SDS-PAGE.
> 95 % as determined by SEC-HPLC. |
分子量 | 15.4 kDa (predicted); 18.52 kDa (reducing conditions) |
内毒素 | < 0.01 EU/μg of the protein as determined by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
复溶方法 | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Interleukin-2, also known as a T-cell growth factor, TCGF, Aldesleukin, and IL2, is a secreted protein that belongs to the IL-2 family. Interleukin-2 / IL-2 was the first interleukin molecule to be discovered. Interleukin-2 / IL-2 molecule was first purified to homogeneity by immunoaffinity chromatography by Kendall Smith and his team at Dartmouth Medical School. Interleukin-2 / IL-2 was also the first cytokine shown to mediate its effects via a specific IL-2 receptor, and it was also the first interleukin to be cloned and expressed from a complementary DNA (cDNA) library. Interleukin-2 / IL-2 was designated number 2 because Smith's data at the time indicated that IL-1, produced by macrophages, facilitates IL-2 production by T lymphocytes (T cells).Interleukin-2 / IL-2 is produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Interleukin-2 / IL-2 is normally produced by the body during an immune response. When environmental substances (molecules or microbes) gain access to the body, these substances (termed antigens) are recognized as foreign by antigen receptors that are expressed on the surface of lymphocytes. Antigen binding to the T cell receptor (TCR) stimulates the secretion of Interleukin-2 / IL-2 and the expression of IL-2 receptors IL-2R. The IL-2 / IL-2R interaction then stimulates the growth, differentiation, and survival of antigen-selected cytotoxic T cells via the activation of the expression of specific genes. Interleukin-2 / IL-2 can stimulate B-cells, monocytes, lymphokine-activated killer cells, natural killer cells, and glioma cells. The World Reference Standard for Interleukin-2 / IL-2 is produced by the National Institute of Biological Standards and Control in the UK. A recombinant form of Interleukin-2 / IL-2 for clinical use is manufactured by Chiron Corporation with the brand name Proleukin. It has been approved by the Food and Drug Administration (FDA) for the treatment of cancers (malignant melanoma, renal cell cancer), and is in clinical trials for the treatment of chronic viral infections, and as a booster (adjuvant) for vaccines. The use of Interleukin-2 / IL-2 in HIV therapy is ineffective.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.